Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Johnson & Johnson
31 Articles Available
0
2
Can't find what you're looking for? Try our
advanced search
.
COVID-19 Trials
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
PR-M09-20-27
Vaccine
European Commission Concludes Further Talks to Secure J&J COVID-19 Vaccine
PR-M08-20-NI-24
COVID-19 Vaccine
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
PR-M08-20-NI-11
HIV Prevention
Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine with the Imbokodo Study
PR-M07-20-NI-026
COVID-19 Vaccine Manufacturing
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
PR-M07-20-NI-007
COVID-19 Vaccine
Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
PR-M04-20-NI-044
Vaccine
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19
PR-M03-20-NI-045
Coronavirus
J&J Cites Lack of Evidence for HIV Treatment Against COVID-19
PR-M03-20-NI-026
Collaboration
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
PR-M02-20-NI-017
Depression
Trump Urges VA to Use Spravato
PAO-M00-19-NI-007
Opioid Crisis
J&J Awaits Judge’s Decision in Lawsuit Filed by Oklahoma Over the Opioid Crisis
PAO-M07-19-NI-021
FDA Approval
FDA Grants Additional Myeloma Approval to J&J’s Darzalex
PAO-M07-19-NI-014
Opioid Crisis
Oklahoma vs. Johnson & Johnson Opioid Crisis Trial
PAO-M06-19-NI-006
Oncology
FDA Will Use Real-Time Oncology Review for Prostate Cancer Drug
PAO-M05-19-NI-012
Diabetes
J&J Believes its Diabetes Drug Invokana Is A Game Changer
PAO-M04-19-NI-021
FDA Approval
J&J’s Bladder Cancer Drug Gets Accelerated FDA Approval
PAO-M04-19-NI-019
Acquisition
Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.
PR-M02-19-NI-036
Financial Results
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019
PR-M01-19-NI-010
Investment
J&J Anticipates Growth
PAO-M09-18-NI-014
Regulatory
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
PR-M08-18-NI-093
Genome
Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center
PR-M06-18-NI-075
Real-World Study
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli
PR-M05-18-NI-101
Acquisition
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens
PR-M05-18-NI-021
Study
Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
PR-M05-18-NI-010
«
0
2
»
.svg)
